David Day and a lifetime of missed moments
8 June 2018
“I couldn’t eat. Barely slept. I was the one to tell Dave it was all over. All Dave said was ‘my poor, poor babies’.” Jenny, David’s wife.
When David lost his life last year, he was 33, with three daughters under six.
David Day was one of the 20% of people with advanced melanoma have primary resistance to new drugs with ‘super progression' and we need to find out why.
The greatest challenge our clinicians currently face in treating melanoma is ‘super progression’.
Amid all our success stories, there is still a group of people with advanced melanoma for whom absolutely nothing works. About 20% of patients our medical oncologists see with advanced melanoma fall into this category.
Super progressors do not respond to existing treatments. Within a few short months, their disease progresses aggressively and relentlessly and we cannot save them.
David Day, was one such patient —a lovely young father with a wonderful family — who died last year.
The most agonising thing about patients like David is that at present, we just don’t know why they super progress.
Dr Inês Silva was part of the clinical team which treated David Day. She was studying at MIA as a Medical Oncology Fellow from Portugal. David had such a profound impact on Inês, that on completion of her Fellowship, she decided to stay on at MIA as a Research Scientist in an all-out attempt to find answers for super progressors.
Inês and the MIA research team collected blood and melanoma tissue samples from David during his treatment. They also collected similar samples from other advanced melanoma patients who have not responded to immunotherapy.
By studying the genomic profile and protein expression in each of these patients’ tumours, Ines and the MIA research team hope to understand why each drug failed to work, paving the way for new, and potentially life-saving therapies.
While there is some existing grant funding to cover her salary, a dedicated Research Scientist like Inês can’t do it alone.
We are relying on you and on the support of our donor community to collectively fund this research project including research assistants’ salaries, PhD student scholarship top-ups, equipment, and state-of-the-art research technologies such as DNA, RNA and cell sequencing. All are key to understanding and solving primary resistance and super progression.
David was a sweet, humble family man. He was a high-achiever, had forged an exceptional career as a computer engineer for Google and made a loving, happy life raising his three daughters Charlotte, 7, Emma, 5, and Annie, now 1, with his wife Jenny, his childhood sweetheart since Year 9.
Just before Christmas 2016, with Jenny heavily pregnant with little Annie, Dave found a lump under his left arm. He had Stage III melanoma. Half way through his treatment, David found another lump under his arm and a new tumour was discovered on his left hip. His melanoma had progressed to Stage IV.
In March 2017, David and Jenny were referred to Melanoma Institute Australia. He started on a clinical trial and at first, his scans looked promising.
After starting treatment, another painful melanoma appeared on David’s wrist. In the next three months, tumours sprang up in his spleen, lungs, pancreas, bones, under his skin — with up to 30 more in his liver. Even though immune cells were present, David was super progressing.
As the months passed, David suffered extreme pain, liver damage, rapid weight loss, blurred vision and internal bleeding. The clinical team switched to chemotherapy as a last resort and Annie’s christening was pushed forward.
On 25 August 2017, Jenny had the worst imaginable task of explaining to her soul mate that nothing more could be done for him.
“I was the one to tell him it was over. All he could say was “My poor, poor babies”. My heart ached. I had lost 15kg over the past five months from the stress of the whole situation. My milk dried up and I couldn’t feed Annie. It ate away at me while I put on a brave face for Dave and the kids,” says Jenny.
Jenny has very generously shared her painful story in the hope that it will help raise funds to crack the riddle of super progression.
Please give today to save someone you know from the ravages of melanoma in the future, and give them what David didn’t have- the opportunity to enjoy a lifetime of special moments with their loved ones.
Professor Georgina Long named as one of world's most highly cited researchers
Professor Georgina Long is among only 12 researchers from the University of Sydney to be named in the 2018 Highly Cited Researchers List.
Aussies need to protect themselves from 'everyday' sun damage
‘Wearing sunscreen should be as automatic as wearing a seatbelt. Both are potential life savers.’
The Poche Centre to host 3D total-body imaging system as part of world-first initiative to save lives from melanoma
A prestigious $10 million Australian Cancer Research Foundation grant has been awarded to ACEMID, an initiative that aims to use 3D total-body imaging and a remote medicine network to improve the detection and diagnosis of early-stage melanoma.
Major award for world-leaders in melanoma research
Professor Georgina Long and Professor Richard Scolyer have been recognised as world leaders in melanoma research for their ground-breaking work that has changed the diagnosis and treatment landscape of melanoma world-wide, and tripled the life-expectancy of advanced melanoma patients.
Melanoma Institute Australia shines at prestigious Cancer Research Awards
Leading researchers from Melanoma Institute Australia have taken out the top accolades at the NSW Premier’s Awards for Outstanding Cancer Research.
Women of MIA lead the way in melanoma research at SMR
An impressive contingent of female delegates from Melanoma Institute Australia have presented findings across the whole spectrum of melanoma research at the Society for Melanoma Research 2018 Congress in Manchester, England.
Immune cell research presented at SMR
Over 800 researchers and clinicians from around the world were welcomed to Manchester for the 15th International Congress of the Society for Melanoma Research (SMR). Melanoma Institute Australia (MIA) has again sent an impressive number of delegates to present both oral presentations and posters with the latest in translational research.
Professor Georgina Long makes history as the first woman and first Australian to lead the Society for Melanoma Research
Professor Georgina Long makes history as the first woman and first Australian to lead the world’s most prestigious international melanoma research association.
Patients to benefit from updated skin tumour publications
Two publications co-edited by MIA Co-Medical Director Professor Richard Scolyer are now available to healthcare professionals. They aim to provide assistance in the care and management of patients with skin cancer, including melanoma.
SunSafe Student Ambassador Program
Melanoma Institute Australia has introduced a new educational program to teach teenagers about the dangers of melanoma and the importance of sun safety.
International collaboration the key to increasing survival
"International collaboration remains the key to ensuring this pioneering research continues so we can increase survival rates for advanced melanoma patients and move us closer to achieving our goal of zero deaths from melanoma," says Professor Georgina Long, of the clinical trial results presented at ESMO 2018.
High-risk Stage III melanoma patients to benefit from Australia/Netherlands collaboration
Research that could change clinical practice for high-risk Stage III melanoma patients has been presented at the European Society for Medical Oncology (ESMO) Congress in Munich.
Monthly dose of immunotherapy allows flexibility for patients undergoing treatment
A larger, monthly dose of immunotherapy can give melanoma patients more freedom without sacrificing effectiveness.
Australia's best minds in melanoma research converge on Melbourne
The Australasian Melanoma Conference, hosted by the Australasian Melanoma Conference Committee, was held in Melbourne on the weekend, with many of MIA's clinicians in attendance.
Nobel Prize for novel cancer therapies
The two men who discovered checkpoint inhibitors, the brakes of the immune system, were awarded the Nobel Prize in Physiology or Medicine on Monday, October 1.
World Health Organisation launches 4th edition of Classification of Skin Tumours
The World Health Organisation (WHO) is releasing the 4th edition of Classification of Skin Tumours.
Professor John Thompson awarded prestigious 2018 RPA Foundation Research Medal
Former Executive Director of Melanoma Institute Australia Professor John Thompson awarded the prestigious 2018 RPA Foundation Research Medal.
Support PBS listing for pembrolizumab
Clinicians, patients and other stakeholders in the cancer community are invited to make submissions in support of the PBS listing for pembrolizumab.
World Congress on Cancers of the Skin 2018
The World Congress on Cancers of the Skin 2018 has featured many minds from MIA sharing their expertise and wealth of knowledge with over 1000 attendees from around the world.
Melanoma Institute Australia welcomes new CEO Matthew Browne
Melanoma Institute Australia is delighted to announce the appointment of Matthew Browne as Chief Executive Officer (CEO).